Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | PIP5K1C | O60331 | 2/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.40 |
| ▸ | EP300 | Q09472 | 4/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | RBP4 | P02753 | 6/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4795587 | 0.83 | NPC1 (0.48) | NPC1RAB9APIP5K1CRBP4 | |
| SCHEMBL5953472 | 0.81 | HCAR2 (0.56) | CREBBPEP300BRD4 | |
| SCHEMBL22395319 | 0.77 | PIP5K1C (0.61) | NPC1RAB9APIP5K1C | |
| SCHEMBL22029695 | 0.74 | CREBBP (0.42) | CREBBPEP300BRD4RBP4 | |
| SCHEMBL4778041 | 0.73 | NPC1 (0.60) | NPC1RAB9A | |
| SCHEMBL22395120 | 0.73 | PIP5K1C (0.56) | NPC1RAB9APIP5K1C | |
| SCHEMBL20818349 | 0.72 | CREBBP (0.44) | CREBBPEP300BRD4 | |
| SCHEMBL17785675 | 0.72 | CREBBP (0.47) | PIP5K1CCREBBPEP300BRD4 | |
| SCHEMBL4761723 | 0.72 | CREBBP (0.47) | CREBBPEP300BRD4 | |
| SCHEMBL17785865 | 0.72 | CREBBP (0.44) | CREBBPEP300BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | NPC1 1992/4885RAB9A 440/4885PIP5K1C 188/4885 |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | NPC1 2050/4885RAB9A 593/4885PIP5K1C 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.